drug_type
RELEVANT_DRUG
intervention_type
Antibody–Drug Conjugate (ADC)
drug_description
A HER2-targeted antibody–drug conjugate delivering the maytansinoid DM1 (microtubule inhibitor) via a non-cleavable linker; inhibits mitosis and mediates HER2 signaling blockade and ADCC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Trastuzumab Emtansine
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
HER2-targeted monoclonal antibody-drug conjugate (trastuzumab linked via a non-cleavable linker to the maytansinoid DM1). After binding HER2, it is internalized and degraded to release a DM1 catabolite that inhibits microtubules, causing mitotic arrest and apoptosis; the trastuzumab component also blocks HER2 signaling and mediates ADCC.
drug_name
Trastuzumab emtansine (T-DM1)
nct_id_drug_ref
NCT06265428